-
1
-
-
84969908932
-
-
Atlanta, GA: American Cancer Society
-
American Cancer Society. Cancer Facts and Figures 2015. Atlanta, GA: American Cancer Society; 2015.
-
(2015)
Cancer Facts and Figures 2015
-
-
-
2
-
-
84855999990
-
Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer
-
Nagel CI, Backes FJ, Hade EM, et al. Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. Gynecol Oncol. 2012;124(2):221-224.
-
(2012)
Gynecol Oncol.
, vol.124
, Issue.2
, pp. 221-224
-
-
Nagel, C.I.1
Backes, F.J.2
Hade, E.M.3
-
3
-
-
79959774261
-
Recent progress in the diagnosis and treatment of ovarian cancer
-
Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183-203.
-
(2011)
CA Cancer J Clin.
, vol.61
, Issue.3
, pp. 183-203
-
-
Jelovac, D.1
Armstrong, D.K.2
-
4
-
-
46749096115
-
Chemotherapy dosing strategies in the obese, elderly, and thin patient: Results of a nationwide survey
-
Field KM, Kosmider S, Jefford M, et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract. 2008;4(3):108-113.
-
(2008)
J Oncol Pract.
, vol.4
, Issue.3
, pp. 108-113
-
-
Field, K.M.1
Kosmider, S.2
Jefford, M.3
-
5
-
-
84862986506
-
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline
-
Griggs JJ, Mangu PB, Anderson H, et al; American Society of Clinical Oncology. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30(13): 1553-1561.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.13
, pp. 1553-1561
-
-
Griggs, J.J.1
Mangu, P.B.2
Anderson, H.3
-
7
-
-
25444485782
-
The impact of obesity on the incidence and treatment of gynecologic cancers: A review
-
Modesitt SC, van Nagell JR Jr. The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet Gynecol Surv. 2005;60(10):683-692.
-
(2005)
Obstet Gynecol Surv.
, vol.60
, Issue.10
, pp. 683-692
-
-
Modesitt, S.C.1
Van Nagell, J.R.2
-
8
-
-
67349205883
-
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
-
Ekhart C, Rodenhuis S, Schellens JH, Beijnen JH, Huitema AD. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol. 2009;64(1):115-122.
-
(2009)
Cancer Chemother Pharmacol.
, vol.64
, Issue.1
, pp. 115-122
-
-
Ekhart, C.1
Rodenhuis, S.2
Schellens, J.H.3
Beijnen, J.H.4
Huitema, A.D.5
-
10
-
-
84937522221
-
The HMO Research Network Virtual Data Warehouse: A public data model to support collaboration
-
Ross TR, Ng D, Brown JS, et al. The HMO Research Network Virtual Data Warehouse: a public data model to support collaboration. EGEMS (Wash DC). 2014;2(1):1049.
-
(2014)
EGEMS (Wash DC).
, vol.2
, Issue.1
, pp. 1049
-
-
Ross, T.R.1
Ng, D.2
Brown, J.S.3
-
12
-
-
0025663391
-
The calculation of received dose intensity
-
Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol. 1990;8(12): 1935-1937.
-
(1990)
J Clin Oncol.
, vol.8
, Issue.12
, pp. 1935-1937
-
-
Hryniuk, W.M.1
Goodyear, M.2
-
13
-
-
0041736242
-
Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy
-
Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat. 2003;81(1):21-31.
-
(2003)
Breast Cancer Res Treat.
, vol.81
, Issue.1
, pp. 21-31
-
-
Griggs, J.J.1
Sorbero, M.E.2
Stark, A.T.3
Heininger, S.E.4
Dick, A.W.5
-
14
-
-
33846933756
-
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy
-
Griggs JJ, Culakova E, Sorbero ME, et al. Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol. 2007;25(3):277-284.
-
(2007)
J Clin Oncol.
, vol.25
, Issue.3
, pp. 277-284
-
-
Griggs, J.J.1
Culakova, E.2
Sorbero, M.E.3
-
15
-
-
84875451592
-
Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer
-
Hanna RK, Poniewierski MS, Laskey RA, et al. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2013;129(1):74-80.
-
(2013)
Gynecol Oncol.
, vol.129
, Issue.1
, pp. 74-80
-
-
Hanna, R.K.1
Poniewierski, M.S.2
Laskey, R.A.3
-
16
-
-
84897082114
-
Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS)
-
Au-Yeung G, Webb PM, DeFazio A, Fereday S, Bressel M, Mileshkin L. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol. 2014; 133(1):16-22.
-
(2014)
Gynecol Oncol.
, vol.133
, Issue.1
, pp. 16-22
-
-
Au-Yeung, G.1
Webb, P.M.2
DeFazio, A.3
Fereday, S.4
Bressel, M.5
Mileshkin, L.6
-
17
-
-
80051548582
-
Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer
-
Fauci JM, Whitworth JM, Schneider KE, et al. Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer. Gynecol Oncol. 2011;122 (3):532-535.
-
(2011)
Gynecol Oncol.
, vol.122
, Issue.3
, pp. 532-535
-
-
Fauci, J.M.1
Whitworth, J.M.2
Schneider, K.E.3
-
18
-
-
65549105066
-
Treatment quality and outcomes of African American versus white breast cancer patients: Retrospective analysis of Southwest Oncology studies S8814/S8897
-
Hershman DL, Unger JM, Barlow WE, et al. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol. 2009;27(13): 2157-2162.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.13
, pp. 2157-2162
-
-
Hershman, D.L.1
Unger, J.M.2
Barlow, W.E.3
-
19
-
-
84899638961
-
The influence of comorbidity on mortality in ovarian cancer patients
-
Stålberg K, Svensson T, Lönn S, Kieler H. The influence of comorbidity on mortality in ovarian cancer patients. Gynecol Oncol. 2014;133(2):298-303.
-
(2014)
Gynecol Oncol.
, vol.133
, Issue.2
, pp. 298-303
-
-
Stålberg, K.1
Svensson, T.2
Lönn, S.3
Kieler, H.4
-
20
-
-
84876290864
-
Prevalence and incidence of comorbidities in elderly women with ovarian cancer
-
Chia VM, O'Malley CD, Danese MD, et al. Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol. 2013;129(2):346-352.
-
(2013)
Gynecol Oncol.
, vol.129
, Issue.2
, pp. 346-352
-
-
Chia, V.M.1
O'Malley, C.D.2
Danese, M.D.3
-
21
-
-
84859625302
-
Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy
-
Rodriguez N, Rauh-Hain JA, Shoni M, et al. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012;125(2):362-366.
-
(2012)
Gynecol Oncol.
, vol.125
, Issue.2
, pp. 362-366
-
-
Rodriguez, N.1
Rauh-Hain, J.A.2
Shoni, M.3
-
22
-
-
84920733816
-
CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy
-
Pelissier A, Bonneau C, Chéreau E, et al. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2014;135(3):542-546.
-
(2014)
Gynecol Oncol.
, vol.135
, Issue.3
, pp. 542-546
-
-
Pelissier, A.1
Bonneau, C.2
Chéreau, E.3
-
23
-
-
43049127201
-
Does body mass index affect progression-free or overall survival in patients with ovarian cancer results from SCOTROC i trial
-
Barrett SV, Paul J, Hay A, Vasey PA, Kaye SB, Glasspool RM; Scottish Gynaecological Cancer Trials Group. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? results from SCOTROC I trial. Ann Oncol. 2008;19(5):898-902.
-
(2008)
Ann Oncol.
, vol.19
, Issue.5
, pp. 898-902
-
-
Barrett, S.V.1
Paul, J.2
Hay, A.3
Vasey, P.A.4
Kaye, S.B.5
Glasspool, R.M.6
-
24
-
-
44549088304
-
Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study
-
Wright JD, Tian C, Mutch DG, et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109(3):353-358.
-
(2008)
Gynecol Oncol.
, vol.109
, Issue.3
, pp. 353-358
-
-
Wright, J.D.1
Tian, C.2
Mutch, D.G.3
-
25
-
-
84857436406
-
The impact of body weight on ovarian cancer outcomes
-
Backes FJ, Nagel CI, Bussewitz E, Donner J, Hade E, Salani R. The impact of body weight on ovarian cancer outcomes. Int J Gynecol Cancer. 2011;21(9):1601-1605.
-
(2011)
Int J Gynecol Cancer.
, vol.21
, Issue.9
, pp. 1601-1605
-
-
Backes, F.J.1
Nagel, C.I.2
Bussewitz, E.3
Donner, J.4
Hade, E.5
Salani, R.6
-
26
-
-
84881479689
-
Chemotherapy dosing in overweight and obese patients with cancer
-
Lyman GH, Sparreboom A. Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol. 2013;10(8):451-459.
-
(2013)
Nat Rev Clin Oncol.
, vol.10
, Issue.8
, pp. 451-459
-
-
Lyman, G.H.1
Sparreboom, A.2
-
27
-
-
0027281461
-
The impact of received dose intensity on the outcome of advanced ovarian cancer
-
Repetto L, Pace M, Mammoliti S, et al. The impact of received dose intensity on the outcome of advanced ovarian cancer. Eur J Cancer. 1993;29A(2):181-184.
-
(1993)
Eur J Cancer.
, vol.29 A
, Issue.2
, pp. 181-184
-
-
Repetto, L.1
Pace, M.2
Mammoliti, S.3
-
28
-
-
84880075063
-
Functional range of creatinine clearance for renal drug dosing: A practical solution to the controversy of which weight to use in the Cockcroft-Gault equation
-
Brown DL, Masselink AJ, Lalla CD. Functional range of creatinine clearance for renal drug dosing: a practical solution to the controversy of which weight to use in the Cockcroft-Gault equation. Ann Pharmacother. 2013;47(7-8):1039-1044.
-
(2013)
Ann Pharmacother.
, vol.47
, Issue.7-8
, pp. 1039-1044
-
-
Brown, D.L.1
Masselink, A.J.2
Lalla, C.D.3
-
29
-
-
84856487711
-
Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010
-
Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491-497.
-
(2012)
JAMA.
, vol.307
, Issue.5
, pp. 491-497
-
-
Flegal, K.M.1
Carroll, M.D.2
Kit, B.K.3
Ogden, C.L.4
-
30
-
-
0037629061
-
Stage at diagnosis of ovarian cancer in the United States, 1992-1997
-
Goodman MT, Correa CN, Tung KH, et al. Stage at diagnosis of ovarian cancer in the United States, 1992-1997. Cancer. 2003;97(10)(suppl):2648-2659.
-
(2003)
Cancer.
, vol.97
, Issue.10
, pp. 2648-2659
-
-
Goodman, M.T.1
Correa, C.N.2
Tung, K.H.3
|